Judy Olian Sells 1,800 Shares of United Therapeutics (NASDAQ:UTHR) Stock

Key Points

• Judy Olian, a director at United Therapeutics, sold 1,800 shares at an average price of $415.43, resulting in a total transaction of approximately $747,774, which has decreased her ownership by 26.30%.
• United Therapeutics posted earnings of $6.41 per share for the last quarter, falling short of analysts' expectations of $6.80, with revenue of $798.60 million.
• Analysts have mixed ratings for United Therapeutics, with target prices ranging from $328.00 to $564.00, and a consensus target price of $438.85.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) Director Judy Olian sold 1,800 shares of the business's stock in a transaction dated Friday, September 19th. The shares were sold at an average price of $415.43, for a total transaction of $747,774.00. Following the completion of the sale, the director directly owned 5,045 shares of the company's stock, valued at $2,095,844.35. This represents a 26.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Trading Up 1.9%

NASDAQ UTHR traded up $7.70 during trading on Friday, reaching $417.57. The company's stock had a trading volume of 1,940,160 shares, compared to its average volume of 574,873. The firm has a 50 day moving average price of $327.11 and a 200 day moving average price of $309.92. The firm has a market capitalization of $18.84 billion, a price-to-earnings ratio of 16.30, a price-to-earnings-growth ratio of 6.15 and a beta of 0.62. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $436.95.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). The firm had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. United Therapeutics's quarterly revenue was up 11.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.85 earnings per share. On average, equities analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on UTHR. Wells Fargo & Company boosted their target price on shares of United Therapeutics from $295.00 to $414.00 and gave the company an "equal weight" rating in a research report on Wednesday, September 3rd. Jefferies Financial Group upped their price target on shares of United Therapeutics from $432.00 to $564.00 and gave the company a "buy" rating in a research report on Tuesday, September 2nd. Morgan Stanley lowered their target price on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a report on Thursday, July 10th. HC Wainwright upped their target price on shares of United Therapeutics from $400.00 to $500.00 and gave the stock a "buy" rating in a report on Friday, September 5th. Finally, Bank of America upped their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a report on Tuesday, September 2nd. Nine analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, United Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $438.85.

Hedge Funds Weigh In On United Therapeutics

Several large investors have recently modified their holdings of UTHR. XTX Topco Ltd purchased a new position in United Therapeutics during the first quarter valued at approximately $313,000. Allianz Asset Management GmbH increased its holdings in United Therapeutics by 96.9% during the 1st quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock worth $20,832,000 after acquiring an additional 33,254 shares during the period. LPL Financial LLC increased its holdings in United Therapeutics by 77.3% during the 1st quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock worth $7,783,000 after acquiring an additional 11,007 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in United Therapeutics by 11.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock worth $1,129,000 after acquiring an additional 376 shares during the period. Finally, Concurrent Investment Advisors LLC bought a new stake in United Therapeutics during the 1st quarter worth approximately $227,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.